We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+38.53%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$524M
AUM Growth
+$84.8M
(+19%)
Cap. Flow
-$21.1M
Cap. Flow
% of AUM
-4.01%
Top 10 Holdings %
Top 10 Hldgs %
56.21%
Holding
96
New
14
Increased
18
Reduced
28
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$11.2M |
| 2 |
Denali Therapeutics
DNLI
|
+$8.64M |
| 3 |
Insulet
PODD
|
+$8.5M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$5.91M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$3.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$21M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$16.5M |
| 3 |
Biohaven
BHVN
|
+$7.62M |
| 4 |
MBX
MBX Biosciences
MBX
|
+$5.72M |
| 5 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.52% |
| 2 | Miscellaneous | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Foghorn Therapeutics
FHTX
$356M
| $546K | 0.1% |
111,859
| – | – |
|
77
Accuray
ARAY
$32.7M
| $433K | 0.08% |
1,680,508
| – | – |
|
78
Q32 Bio
QTTB
$447M
| $419K | 0.08% |
+32,896
| New | +$275K |
|
79
Nuvectis Pharma
NVCT
$775M
| $368K | 0.07% |
+20,000
| New | +$224K |
|
80
Compugen
CGEN
$246M
| $360K | 0.07% |
168,232
-89,551
| -35% | -$224K |
|
81
iBio
IBIO
$67.6M
| $298K | 0.06% |
170,053
-23,585
| -12% | -$42.2K |
|
|
AUTL
82
Autolus Therapeutics
AUTL
$623M
| $287K | 0.05% |
179,316
| – | – |
|
|
BCYC
83
Bicycle Therapeutics
BCYC
$294M
| $273K | 0.05% |
64,492
| – | – |
|
84
Tenaya Therapeutics
TNYA
$155M
| $222K | 0.04% |
+300,000
| New | +$228K |
|
85
Verrica Pharmaceuticals
VRCA
$97.7M
| $145K | 0.03% |
23,750
-129,962
| -85% | -$810K |
|
86
enGene Therapeutics
ENGN
$122M
| $129K | 0.02% |
74,650
-112,703
| -60% | -$460K |
|
|
KARD
87
Kardigan Inc
KARD
$1.87B
| $119K | 0.02% |
+5,000
| New | +$116K |
|
88
ADC Therapeutics
ADCT
$146M
| $82.5K | 0.02% |
77,081
+5,000
| +7% | +$14.6K |
|
|
DAWN
89
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-978,463
| Closed | -$21M |
|
90
Fulcrum Therapeutics
FULC
$294M
| – | – |
-205,000
| Closed | -$1.57M |
|
|
KALV
91
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-267,402
| Closed | -$5.38M |
|
92
Karyopharm Therapeutics
KPTI
$42.4M
| – | – |
-45,800
| Closed | -$255K |
|
93
NewAmsterdam Pharma
NAMS
$3.1B
| – | – |
-20,000
| Closed | -$640K |
|
94
Neumora Therapeutics
NMRA
$261M
| – | – |
-70,000
| Closed | -$137K |
|
95
Oric Pharmaceuticals
ORIC
$1.37B
| – | – |
-98,724
| Closed | -$945K |
|
|
ZBIO
96
Zenas BioPharma
ZBIO
$2.04B
| – | – |
-42,500
| Closed | -$831K |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, DAFNA Capital Management held 96 positions worth $524M, up 19% from $440M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
DAFNA Capital Management withdrew a net $21.1M in Q2 2026, closing 8 positions and reducing 28 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in NervGen Pharma worth $2.16M.
- DAFNA Capital Management's largest Q2 2026 buy was NervGen Pharma: 1,050,000 shares worth $2.16M.
- DAFNA Capital Management added most to Nektar Therapeutics in Q2 2026, an estimated $11.2M increase.
- DAFNA Capital Management's biggest Q2 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $16.5M.
- DAFNA Capital Management fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $21M.
- DAFNA Capital Management's ten largest holdings make up 56% of its $524M portfolio in Q2 2026.
- DAFNA Capital Management opened 14 new positions and closed 8 in Q2 2026.
- DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $524M.
Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.